MyFinsight
Home
Blog
About
Contact
Download
Download image
Net income
$1,292,900K
(-20.79%↓ Y/Y)
Depreciation and
amortization
$779,900K
(15.85%↑ Y/Y)
Deferred income taxes
$361,600K
(328.72%↑ Y/Y)
Share-based compensation
$290,800K
(-0.14%↓ Y/Y)
Amortization of acquired
inventory step-up
$240,800K
(4.70%↑ Y/Y)
Accrued expense and
other current...
$171,100K
(595.53%↑ Y/Y)
Accounts receivable
-$102,700K
(53.80%↑ Y/Y)
Acquired in-process
research and development
$85,000K
Other
-$68,300K
(57.21%↑ Y/Y)
Impairment of rou asset
$52,900K
Contingent consideration
-$33,600K
(-21.30%↓ Y/Y)
Excess and
obsolescence charges related...
$29,200K
(-71.34%↓ Y/Y)
(gain) loss on
strategic investments
-$19,300K
(80.97%↑ Y/Y)
Impairment of intangible
assets
$7,900K
(-86.88%↓ Y/Y)
Net cash flow
provided by (used in)...
$2,204,600K
(-23.33%↓ Y/Y)
Canceled cashflow
$1,331,400K
Net increase
(decrease) in cash and cash...
$531,600K
(-61.83%↓ Y/Y)
Canceled cashflow
$1,673,000K
Income tax assets and
liabilities
-$958,100K
(-1320.51%↓ Y/Y)
Other changes in
operating assets and...
-$248,000K
(-38.78%↓ Y/Y)
Inventory
$64,700K
(-76.37%↓ Y/Y)
Due from anti-cd20
therapeutic programs
$60,600K
(115.66%↑ Y/Y)
Proceeds from sales of
strategic investments
$56,700K
(-60.82%↓ Y/Y)
Other
-$42,900K
(-1012.77%↓ Y/Y)
Proceeds from sales and
maturities of marketable...
$23,000K
Proceeds from borrowings
$1,733,100K
Other
$5,000K
(327.27%↑ Y/Y)
Net cash flow
provided by (used in)...
-$1,371,100K
(-71.56%↓ Y/Y)
Net cash flow
provided by (used in)...
-$301,900K
(55.83%↑ Y/Y)
Canceled cashflow
$122,600K
Canceled cashflow
$1,738,100K
Purchases of marketable
securities
$1,258,300K
Purchases of property,
plant and equipment
$153,800K
(0.07%↑ Y/Y)
Repayments of borrowings
$1,750,000K
Acquired in-process
research and development
$50,000K
Acquisitions of intangible
assets
$31,600K
(-84.67%↓ Y/Y)
Contingent consideration
payments
$280,000K
Payments related to
issuance of stock for...
$10,000K
(-68.05%↓ Y/Y)
Back
Back
Cash Flow
source: myfinsight.com
Biogen-svg
BIOGEN INC. (BIIB)
Biogen-svg
BIOGEN INC. (BIIB)